CN107693598A - A kind of compound preparation of reducing blood lipid and preparation method thereof - Google Patents
A kind of compound preparation of reducing blood lipid and preparation method thereof Download PDFInfo
- Publication number
- CN107693598A CN107693598A CN201711093436.XA CN201711093436A CN107693598A CN 107693598 A CN107693598 A CN 107693598A CN 201711093436 A CN201711093436 A CN 201711093436A CN 107693598 A CN107693598 A CN 107693598A
- Authority
- CN
- China
- Prior art keywords
- parts
- blood lipid
- reducing blood
- compound preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention belongs to pharmaceutical technology field, specifically discloses a kind of compound preparation of reducing blood lipid and preparation method thereof, counts in parts by weight, takes following raw material：15 parts of 14 parts of Lovastatin, 18 parts of nicotinic acid, 15 parts of calcium pantothenate, 13 parts of niacinamide, 0.2 0.5 parts of L arginine, 15 parts of mulberry leaf, 24 parts of balsam pear, 15 parts of chrysanthemum, 25 parts of ginseng, 1 10 parts of cassia seed, 25 parts of hawthorn and apple powder.The compound preparation of reducing blood lipid of the present invention is made through rational proportion, can not only reducing blood lipid, additionally it is possible to improves body metabolism function, protection and improves organ function, improves physical function.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of compound preparation of reducing blood lipid and preparation method thereof.
Background technology
Hyperlipidemia refers to cholesterol in serum (TC), triglyceride (TG) and (or) low-density lipoprotein (LDL) mistake
A kind of high and (or) too low serum high-density LP (HDL) whole body Anomalous lipid metablism.Numerous studies data shows, high fat of blood
Disease is the important hazards of cerebral apoplexy, coronary heart disease, myocardial infarction, cardiac sudden death；Other hyperlipemia be also promote hypertension,
The hazards of IGT, diabetes；Hyperlipemia can also result in fatty liver, hepatic sclerosis, cholelithiasis, pancreatitis, eyeground
Bleeding, blindness, peripheral vascular disease, limping, hyperuricemia.Some primary and familial hyperlipidemia patient it may also occur that
The symptom such as xanthoma, embryotoxon around tendon shape, nodositas, palm plane and eye socket.
It is known as adjusting fat most effective at present and wide variety of Western medicine is Statins, but Statins has liver and musclar toxicity
Deng side effect.So research and development combination of Chinese tradiational and Western medicine medicine, which can preferably reduce hyperlipidemia and can, reduces adverse reaction, reduce
Toxicity.Product has its huge social value and economic value.
The content of the invention
In order to solve the above problems, the present invention provides a kind of compound preparation of reducing blood lipid and preparation method thereof, this medicine knot
Close Chinese and western medical theory, rational proportion forms a kind of compound preparation of reducing blood lipid of the present invention, regulation fat metabolism, protection and
Improve organ function, improve physical function.
The technical scheme that the present invention solves above-mentioned technical problem is as follows：A kind of compound preparation of reducing blood lipid, in parts by weight
Meter, is made up of following raw material：Lovastatin 1-4 parts, nicotinic acid 1-8 parts, calcium pantothenate 1-5 parts, niacinamide 1-3 parts, L-arginine
0.2-0.5 parts, mulberry leaf 1-5 parts, balsam pear 2-4 parts, chrysanthemum 1-5 part ginseng 2-5 parts, cassia seed 1-10 parts, hawthorn 2-5 parts and apple
Powder 1-5 parts.
On the basis of above-mentioned technical proposal, the present invention can also do following improvement.
Preferably, a kind of compound preparation of reducing blood lipid, is counted in parts by weight, is made up of following raw material：3 parts of Lovastatin,
5 parts of nicotinic acid, 2 parts of calcium pantothenate, 2 parts of niacinamide, 0.2 part of L-arginine, 4 parts of mulberry leaf, 4 parts of balsam pear, 1 part of chrysanthemum, 2 parts of ginseng, certainly
3 parts of 5 parts of pine torch, 3 parts of hawthorn and apple powder.
Preferably, a kind of compound preparation of reducing blood lipid, is counted in parts by weight, is made up of following raw material：1 part of Lovastatin,
8 parts of nicotinic acid, 1 part of calcium pantothenate, 3 parts of niacinamide, 0.2 part of L-arginine, 5 parts of mulberry leaf, 2 parts of balsam pear, 5 parts of chrysanthemum, 2 parts of ginseng, certainly
5 parts of 10 parts of pine torch, 2 parts of hawthorn and apple powder.
Preferably, a kind of compound preparation of reducing blood lipid, is counted in parts by weight, is made up of following raw material：4 parts of Lovastatin,
1 part of nicotinic acid, 5 parts of calcium pantothenate, 1 part of niacinamide, 0.5 part of L-arginine, 1 part of mulberry leaf, 4 parts of balsam pear, 1 part of chrysanthemum, 5 parts of ginseng, certainly
1 part of 1 part of pine torch, 5 parts of hawthorn and apple powder.
The present invention also provides a kind of preparation method of the compound preparation of reducing blood lipid, comprises the following steps：
Step 1：Based on raw material weight number, following raw material is taken：Lovastatin 1-4 parts, nicotinic acid 1-8 parts, calcium pantothenate 1-5
Part, niacinamide 1-3 parts, L-arginine 0.2-0.5 parts, mulberry leaf 1-5 parts, balsam pear 2-4 parts, chrysanthemum 1-5 parts, ginseng 2-5 parts, Cassia
Sub- 1-10 parts, hawthorn 2-5 parts and apple powder 1-5 parts；
Step 2：Mulberry leaf, balsam pear, chrysanthemum, ginseng, cassia seed, hawthorn and apple powder are mixed, the mixing prepared slices of Chinese crude drugs is obtained, adds
Enter volume fraction be 70% ethanol, 40-60 DEG C of ultrasonic extraction 30min, extract solution, extract solution is freeze-dried, carried
Take thing；
Step 3：Lovastatin, nicotinic acid, calcium pantothenate, niacinamide, L-arginine is added in the extract obtained to step 2 to mix
Close uniformly, tabletting, coating, obtain the compound preparation of reducing blood lipid.
Preferably, a kind of preparation method of the compound preparation of reducing blood lipid, it is characterised in that：The addition of ethanol described in step 2
Amount is (5-10) with the mass ratio for mixing the prepared slices of Chinese crude drugs：1.
Compared with prior art, the beneficial effects of the invention are as follows：
The present invention combines Chinese and western medical theory, and selection function medicine carries out rational proportion, reducing blood lipid of the present invention is made
Compound preparation.The compound preparation of the present invention is made in the present invention by the way of Chinese and Western combines, and not only lipid-lowering effect is notable, and several
Have no adverse reaction, expense is low, and technique is simple, makes the adjusted blood glucose of Impaired Glucose Regulation and fat metabolism, protects and carry
High organ function, improve the multiple benefits such as physical function.
Embodiment
The principles and features of the present invention are described below, and the given examples are served only to explain the present invention, is not intended to limit
Determine the scope of the present invention.
Embodiment 1
A kind of preparation method of the compound preparation of reducing blood lipid, comprises the following steps：
Step 1：Take following raw material：Lovastatin 3g, nicotinic acid 5g, calcium pantothenate 2g, niacinamide 2g, L-arginine 0.2g, mulberry
Leaf 4g, balsam pear 4g, chrysanthemum 1g, ginseng 2g, cassia seed 5g, hawthorn 3g and apple powder 3g.
Step 2：Mulberry leaf, balsam pear, chrysanthemum, ginseng, cassia seed, hawthorn and apple powder are mixed, the mixing prepared slices of Chinese crude drugs is obtained, adds
Enter the ethanol that 175g volume fractions are 70%, 50 DEG C of ultrasonic extraction 30min, obtain extract solution, extract solution is freeze-dried, carried
Take thing；
Step 3：Lovastatin, nicotinic acid, calcium pantothenate, niacinamide, L-arginine is added in the extract obtained to step 2 to mix
Close uniformly, tabletting, coating, obtain the compound preparation of reducing blood lipid.
Embodiment 2
A kind of preparation method of the compound preparation of reducing blood lipid, comprises the following steps：
Step 1：Take following raw material：Lovastatin 1g, nicotinic acid 8g, calcium pantothenate 1g, niacinamide 3g, L-arginine 0.2g, mulberry
Leaf 5g, balsam pear 2g, chrysanthemum 5g, ginseng 2g, cassia seed 10g, hawthorn 2g and apple powder 5g.
Step 2：Mulberry leaf, balsam pear, chrysanthemum, ginseng, cassia seed, hawthorn and apple powder are mixed, the mixing prepared slices of Chinese crude drugs is obtained, adds
Enter 175g volume fractions be 70% ethanol, 50 DEG C of ultrasonic extraction 30min, extract solution, extract solution is freeze-dried, carried
Take thing；
Step 3：Lovastatin, nicotinic acid, calcium pantothenate, niacinamide, L-arginine is added in the extract obtained to step 2 to mix
Close uniformly, tabletting, coating, obtain the compound preparation of reducing blood lipid.
Embodiment 3
A kind of preparation method of the compound preparation of reducing blood lipid, comprises the following steps：
Step 1：Take following raw material：Lovastatin 4g, nicotinic acid 1g, calcium pantothenate 5g, niacinamide 1g, L-arginine 0.5g, mulberry
Leaf 1g, balsam pear 4g, chrysanthemum 1g, ginseng 5g, cassia seed 1g, hawthorn 5g and apple powder 1g.
Step 2：Mulberry leaf, balsam pear, chrysanthemum, ginseng, cassia seed, hawthorn and apple powder are mixed, the mixing prepared slices of Chinese crude drugs is obtained, adds
Enter 175g volume fractions be 70% ethanol, 50 DEG C of ultrasonic extraction 30min, extract solution, extract solution is freeze-dried, carried
Take thing；
Step 3：Lovastatin, nicotinic acid, calcium pantothenate, niacinamide, L-arginine is added in the extract obtained to step 2 to mix
Close uniformly, tabletting, coating, obtain the compound preparation of reducing blood lipid.
Comparative example：
A kind of preparation method of the compound preparation of reducing blood lipid, comprises the following steps：
Step 1：Take following raw material：Nicotinic acid 1g, calcium pantothenate 5g, niacinamide 1g, L-arginine 0.5g, mulberry leaf 1g, balsam pear 4g,
Chrysanthemum 1g, ginseng 5g, cassia seed 1g, hawthorn 5g and apple powder 1g.
Step 2：Mulberry leaf, balsam pear, chrysanthemum, ginseng, cassia seed, hawthorn and apple powder are mixed, the mixing prepared slices of Chinese crude drugs is obtained, adds
Enter 175g volume fractions be 70% ethanol, 50 DEG C of ultrasonic extraction 30min, extract solution, extract solution is freeze-dried, carried
Take thing；
Step 3：Lovastatin, nicotinic acid, calcium pantothenate, niacinamide, L-arginine is added in the extract obtained to step 2 to mix
Close uniformly, tabletting, coating, obtain the compound preparation of reducing blood lipid.
The compound preparation that above-described embodiment 1 is prepared to gained carries out following pharmacodynamic experiment：
1st, case selection：
200 clinical observations of hyperlipemic patients made a definite diagnosis are selected, the level of patient's triglycerides is above 2.26mmol/L,
Cholesterol level is above 5.17mmol/L, and patient is randomly divided into treatment group and control group, treatment group 100, male 53, female
Property 47, the age 27-85 year, average age 43.5 years old, sick time average out to 6.8 years.Control group 100, wherein male
58, women 42, the age 29-78 year, average age 45.2 years old, sick time average out to 7.2 years.
The course of disease, the degrees of symptoms of two groups of cases for the treatment of group and control group are basically identical, no significant difference, have comparable
Property.
2nd, medicament selection：
The compound preparation of the preparation of the embodiment of the present invention 1 is taken by treatment group, and 2 times a day, 2 tablets each time, 2g/ grains, warm water is sent
Clothes, 10 days are a course for the treatment of, take 2 courses for the treatment of.
Control group takes compound preparation prepared by comparative example of the present invention, and 2 times a day, 1 tablet each time, 2g/ grains, warm water is sent
Clothes, 10 days are a course for the treatment of, take 2 courses for the treatment of.
3rd, efficacy determination：
(1) cure：After medication, cholesterol and triglycerides are in range of normal value, and cholesterol level is less than
5.17mmol/L, content of triglyceride are less than 2.26mmol/L.
(2) it is effective：After medication, blood lipid level has declined, but not drop to normal level.
(3) it is invalid：Patient's blood lipid level is without any downward trend after medication.
4th, result explanation
Treatment group, cure 82, effective 16, invalid 2.
Control group, cure 12, effective 73, invalid 15.
Result above shows that the cure rate for the treatment of group is much larger than control group, and this is also the compound system of the reducing blood lipid of the present invention
Where the advantage of agent, not only lipid-lowering effect is notable, and have no adverse reaction, expense is low, technique is simple, fatty generation can be adjusted
Thank, protect and improve organ function, improve physical function.
Claims (6)
1. a kind of compound preparation of reducing blood lipid, it is characterised in that count, be made up of following raw material in parts by weight：Lovastatin 1-4
Part, nicotinic acid 1-8 parts, calcium pantothenate 1-5 parts, niacinamide 1-3 parts, L-arginine 0.2-0.5 parts, mulberry leaf 1-5 parts, balsam pear 2-4 parts, chrysanthemum
Flower 1-5 parts, ginseng 2-5 parts, cassia seed 1-10 parts, hawthorn 2-5 parts and apple powder 1-5 parts.
2. the compound preparation of a kind of reducing blood lipid according to claim 1, it is characterised in that count in parts by weight, by following
Raw material forms：3 parts of Lovastatin, 5 parts of nicotinic acid, 2 parts of calcium pantothenate, 2 parts of niacinamide, 0.2 part of L-arginine, 4 parts of mulberry leaf, balsam pear 4
3 parts of part, 1 part of chrysanthemum, 2 parts of ginseng, 5 parts of cassia seed, 3 parts of hawthorn and apple powder.
3. the compound preparation of a kind of reducing blood lipid according to claim 1, it is characterised in that count in parts by weight, by following
Raw material forms：1 part of Lovastatin, 8 parts of nicotinic acid, 1 part of calcium pantothenate, 3 parts of niacinamide, 0.2 part of L-arginine, 5 parts of mulberry leaf, balsam pear 2
5 parts of part, 5 parts of chrysanthemum, 2 parts of ginseng, 10 parts of cassia seed, 2 parts of hawthorn and apple powder.
4. the compound preparation of a kind of reducing blood lipid according to claim 1, it is characterised in that count in parts by weight, by following
Raw material forms：4 parts of Lovastatin, 1 part of nicotinic acid, 5 parts of calcium pantothenate, 1 part of niacinamide, 0.5 part of L-arginine, 1 part of mulberry leaf, balsam pear 4
1 part of part, 1 part of chrysanthemum, 5 parts of ginseng, 1 part of cassia seed, 5 parts of hawthorn and apple powder.
5. a kind of preparation method of the compound preparation of reducing blood lipid, it is characterised in that comprise the following steps：
Step 1：Based on raw material weight number, following raw material is taken：Lovastatin 1-4 parts, nicotinic acid 1-8 parts, calcium pantothenate 1-5 parts, cigarette
Acid amides 1-3 parts, L-arginine 0.2-0.5 parts, mulberry leaf 1-5 parts, balsam pear 2-4 parts, chrysanthemum 1-5 parts, ginseng 2-5 parts, cassia seed 1-
10 parts, hawthorn 2-5 parts and apple powder 1-5 parts；
Step 2：Mulberry leaf, balsam pear, chrysanthemum, ginseng, cassia seed, hawthorn and apple powder are mixed, obtain mixing herb powder, adds body
Fraction be 70% ethanol, 40-60 DEG C of ultrasonic extraction 30min, extract solution, extract solution is freeze-dried, obtains extract；
Step 3：Lovastatin, nicotinic acid, calcium pantothenate, niacinamide and L-arginine mixing are added in the extract obtained to step 2
Uniformly, tabletting, it is coated, obtains the compound preparation of reducing blood lipid.
A kind of 6. preparation method of the compound preparation of reducing blood lipid according to claim 5, it is characterised in that：Described in step 2
The addition of ethanol is (5-10) with the mass ratio for mixing the prepared slices of Chinese crude drugs：1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711093436.XA CN107693598A (en) | 2017-11-08 | 2017-11-08 | A kind of compound preparation of reducing blood lipid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711093436.XA CN107693598A (en) | 2017-11-08 | 2017-11-08 | A kind of compound preparation of reducing blood lipid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107693598A true CN107693598A (en) | 2018-02-16 |
Family
ID=61179998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711093436.XA Pending CN107693598A (en) | 2017-11-08 | 2017-11-08 | A kind of compound preparation of reducing blood lipid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107693598A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108478706A (en) * | 2018-04-11 | 2018-09-04 | 福建省中科生物股份有限公司 | It is a kind of to protect cardiovascular composition and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105616481A (en) * | 2016-03-03 | 2016-06-01 | 广东福寿仙生物科技有限公司 | Chinese and western medicine preparation with blood fat reducing function and preparation method thereof |
| CN106075343A (en) * | 2016-07-14 | 2016-11-09 | 高文广 | A kind of blood fat reducing Chinese-western medicine preparation and preparation method thereof |
-
2017
- 2017-11-08 CN CN201711093436.XA patent/CN107693598A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105616481A (en) * | 2016-03-03 | 2016-06-01 | 广东福寿仙生物科技有限公司 | Chinese and western medicine preparation with blood fat reducing function and preparation method thereof |
| CN106075343A (en) * | 2016-07-14 | 2016-11-09 | 高文广 | A kind of blood fat reducing Chinese-western medicine preparation and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108478706A (en) * | 2018-04-11 | 2018-09-04 | 福建省中科生物股份有限公司 | It is a kind of to protect cardiovascular composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538664A (en) | Compositions of ginsenoside Rg3 and ginsenoside Rg5 and their pharmaceutical uses, including antitumor effects | |
| CN102652801A (en) | Chinese herbal medicine tea bag for lowering blood sugar and preventing diabetes mellitus complications | |
| US10350257B2 (en) | Pharmaceutical composition containing complex extract of Crataegi fructus and Citri pericarpium as an active ingredient for treating or preventing obesity or lipid-related metabolic diseases | |
| CN102697982A (en) | Composition having auxiliary blood fat reducing effect and preparation method thereof | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN104055947B (en) | A kind of Chinese medicine composition and preparation method containing grape extract | |
| CN102309004A (en) | Functional health food with lowering cholesterol | |
| KR101886350B1 (en) | Composition containing triterpenoid saponin extracted from the root of Camellia sinensis | |
| CN107693598A (en) | A kind of compound preparation of reducing blood lipid and preparation method thereof | |
| CN101879272B (en) | Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof | |
| CN101879162A (en) | Weight-losing medicament formed by matching alpha-ricinoleic acid ethyl ester with berberine | |
| CN102743458A (en) | Formula of health drug with effects blood fat regulating and immunity increasing | |
| CN102132870A (en) | Diet health-care product and preparation method thereof | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| WO2020063262A1 (en) | Application of 3'-deoxyinosine in preparation of drug, food or health product for multiple disease | |
| CN101112405B (en) | Drug for curing coronary disease and method for preparing the same | |
| CN101053598B (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN107789398A (en) | A kind of pharmaceutical composition of Weight-reducing and lipid-lowering and preparation method thereof | |
| CN103505507A (en) | Traditional Chinese medicine composition containing glossy ganoderma and preparation method of composition | |
| CN109364202A (en) | A kind of composition and its preparation method and application | |
| CN102754831A (en) | Formula of propolis, balsam pear and ginkgo leaf composite preparation with function of reducing blood sugar | |
| CN109316565A (en) | A kind of blood-fat reducing composition and its preparation method and application | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN102552481A (en) | Traditional Chinese medicinal composition with effects of smoothing collaterals and lowering blood pressure and preparation method thereof | |
| CN106822152A (en) | A kind of pharmaceutical composition and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180216 |
|
| RJ01 | Rejection of invention patent application after publication |